Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabelecleucel for EBV-Associated Diseases
NCT00002663Phase 2Completed
- Sponsor
- Atara Biotherapeutics
- Start
- Mar 1995
- Primary completion
- Jul 2019
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of tabelecleucel in Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD), Epstein-Barr virus-associated lymphoma, nasopharyngeal carcinoma (NPC) and 3 more (10 arms), sponsored by Atara Biotherapeutics. Primary endpoint: Objective Response Rate. Started Mar 1995; status: completed.
02
Drugs
tabelecleucel
03
Conditions
Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD)Epstein-Barr virus-associated lymphomanasopharyngeal carcinoma (NPC)leiomyosarcoma (LMS)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT00002663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002663.